Results 211 to 220 of about 3,688,287 (401)

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

Animal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang, Weiran Wu, Qingqing Cai, Jiaxing Wang, Qi Gao, Muhammad Iftikhar, Yulin Bi, Hao Bai, Lihong Gu, Guobin Chang, Shihao Chen   +10 more
wiley   +1 more source

Severe Refractory Asthma and Genetics

, 2012
Young‐Il Koh
openalex   +1 more source

Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland [PDF]

, 2017
Weronika Zastrzeżyńska, Agnieszka Gawlewicz‐Mroczka, Jerzy Soja, Krzysztof Sładek, Jacek Musiał, Stanisława Bazan‐Socha   +5 more
openalex   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair, Bernhard Hellmich, Arnaud Bourdin, David R. W. Jayne, Florence Roufosse, Nader Khalidi, Lena Börjesson Sjö, Ying Fan, Christopher McCrae, Sofia Necander, Eva Rodríguez‐Suárez, Anat Shavit, Claire Walton, Peter A. Merkel, Michael E. Wechsler   +14 more
wiley   +1 more source

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma

Journal of Asthma and Allergy
Hassan Mobayed,1,* Maryam Al-Nesf,1,* Tayseer Ibrahim,1 Sami Aqel,1 Mona Al-Ahmad,2,3 Jean Bousquet4– 6 1Allergy and Immunology Division, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; 2Department of Microbiology, College
Mobayed H, Al-Nesf M, Ibrahim T, Aqel S, Al-Ahmad M, Bousquet J   +5 more
doaj  

P23 Effect of omalizumab on oral corticosteroid requirements of young children with severe asthma; results of a UK survey [PDF]

, 2010
Adaya Kirk, David A. Spencer, Amr Radwan
openalex   +1 more source

Release of Airway Alarmins IL ‐33 and TSLP in Paediatric Acute Severe Asthma: A Case–Control Study [PDF]

Manisha Ramphul, Ian C. Scott, H Killick, Kathryn G. Welsh, Will Monteiro, Christopher E. Brightling, Erol Gaillard   +6 more
openalex   +1 more source

DEVELOPMENT OF THE SEVERE ASTHMA TOOLKIT: A CLINICAL WEBSITE RESOURCE FOR THE MANAGEMENT OF SEVERE TREATMENT‐REFRACTORY ASTHMA [PDF]

, 2018

openalex   +1 more source

Integrated systems modeling of severe asthma: Exploration of IL‐33/ST2 antagonism

, 2022
Kapil Gadkar, Justin Feigelman, Siddharth Sukumaran, Manoj C. Rodrigo, Tracy Staton, Fang Cai, Rebecca N. Bauer, David F. Choy, Cynthia L. Stokes, Heleen Scheerens, Saroja Ramanujan   +10 more
openalex   +1 more source